IGF-DES

Understanding IGF1-LR3

IGF1-LR3 represents an engineered variant of insulin-like growth factor-1, commonly referred to as insulin-like growth factor-1 long arginine 3. This synthetic peptide belongs to a broader classification of IGF-1 analogs that demonstrate significant involvement in cellular mitosis, proliferation mechanisms, and intercellular signaling pathways. While sharing functional similarities with native IGF-1, IGF1-LR3 exhibits reduced affinity for IGF-binding protein interactions. Consequently, the compound demonstrates an extended circulatory retention period, remaining detectable in serum approximately 120-fold longer than endogenous IGF-1. This extended pharmacokinetic profile emerges from deliberate structural modifications—the incorporation of 13 additional amino acid residues at the N-terminal region and the substitution of glutamic acid at position 3 with an arginine moiety.

IGF1-LR3 Structure

Investigational Applications of IGF1-LR3

Cellular Proliferation and Differentiation

Comparable to its parent molecule, IGF1-LR3 functions as a potent mitogenic agent, triggering rapid cellular replication and expansion. The compound exerts preferential effects on connective tissue elements, including skeletal muscle and osseous tissue, while also stimulating proliferative responses in hepatic, renal, neural, integumentary, pulmonary, and hematopoietic compartments. The mechanistic action of IGF-1 should be characterized as a differentiation-promoting hormone because it orchestrates both the multiplication and maturation of cellular populations, enabling appropriate phenotypic specification.

The extended half-life distinguishes IGF1-LR3 from conventional IGF-1, conferring substantially amplified bioactivity. Administration of equivalent IGF1-LR3 quantities generates approximately tripled cellular responses compared to identically dosed IGF-1. A critical distinction exists between hypertrophic and hyperplastic mechanisms: IGF1-LR3 and analogous IGF-1 compounds stimulate numeric expansion of cellular populations rather than individual cell enlargement. This characteristic proves advantageous for developmental processes, as cellular multiplication results in increased muscle mass through escalated fiber quantity rather than isolated fiber dimension.

Lipid Catabolism and Metabolic Disorders

IGF1-LR3 facilitates lipolytic processes through a dual-receptor engagement strategy, binding both IGF-1R and insulin receptor subtypes. These interactions enhance cellular extraction of circulating glucose via muscle, neural, and liver tissues. Such glucose sequestration precipitates systemic glycemia reduction, subsequently dampening adipose tissue accumulation alongside declining circulating insulin, lipid, and triglyceride concentrations. The cumulative effect manifests as diminished adiposity coupled with heightened catabolism.

The glucose-regulatory properties of IGF1-LR3 naturally extend to insulin modulation. Preclinical studies employing murine models of hyperglycemia demonstrate reductions in insulin requirements, with documented decreases approaching 10% in therapeutic dosage needed to maintain euglycemic states. These observations provide potential mechanistic insights for reducing insulin dependency in insulin-resistant populations and may illuminate preventative approaches for glucose-metabolism disorders.

Chronobiological and Longevity Studies

IGF-1 participates in systemic repair and regenerative processes, positioning it as a cytoprotective element against senescence-associated cellular dysfunction. Comparative analysis across bovine species and epidemiological human data suggest that diminished IGF-1 signaling correlates with accelerated aging phenotypes. Contemporary murine investigations examine whether IGF1-LR3 administration might extend survival duration and attenuate age-dependent pathologies including neurodegeneration, sarcopenia, and renal dysfunction. Current data indicate that IGF-1 supplementation can extend lifespan and reduce age-associated morbidity.

Myostatin Antagonism

Myostatin, alternatively designated growth-differentiation factor 8, functions as an endogenous suppressor of myogenic differentiation. The functional inhibition of myostatin represents a therapeutic target for conditions characterized by muscular degeneration and wasting. Myostatin blockade demonstrates potential application in neuromuscular disorders such as Duchenne muscular dystrophy, where the therapeutic objective involves arresting or reversing myofibrillar deterioration. Additionally, myostatin inhibition may benefit individuals experiencing exercise-induced muscle loss or prolonged immobilization-related atrophy. Suppression of this regulatory protein could decelerate proteolytic cascades, preserve contractile function, and reduce associated morbidity.

Experimental evidence from murine dystrophy models illustrates that IGF1-LR3 and related IGF-1 constructs effectively counteract myostatin-mediated myopathy through mechanisms that preserve myocyte viability. IGF1-LR3's extended circulation time renders it particularly effective in myostatin antagonism, functioning through MyoD protein activation, a transcriptional regulator typically expressed during organogenesis but re-engaged following traumatic muscle injury, governing compensatory hypertrophic responses.

Glucocorticoid Co-Administration Effects

Glucocorticosteroids, synthesized principally by the hypothalamic-pituitary-adrenal axis, constitute essential therapeutics for pain management and inflammation suppression in acute illness, infection, neoplasia, and traumatic injury. Despite clinical utility, glucocorticoid administration precipitates substantial adverse effects including immunosuppression and diminished skeletal mineralization. Investigative interest exists regarding IGF1-LR3's potential to mitigate glucocorticoid-induced complications, thereby optimizing therapeutic benefit-to-risk ratios.

Safety and Bioavailability Profile

IGF1-LR3 demonstrates minimal-to-moderate adverse effect potential with limited gastrointestinal absorption but exceptional subcutaneous bioavailability in animal models. Animal-derived dosimetric parameters lack direct translational applicability to human physiology. Products containing IGF1-LR3 remain restricted exclusively to academic and investigational applications and are contraindicated for human consumption.

Contributor Information

Research compilation, integration, and organization was performed by Dr. E. Logan, M.D., who holds a doctoral degree from Case Western Reserve University School of Medicine and a Bachelor of Science credential in molecular biology.

Research Contributors

Dr. Anastasios Philippou, Ph.D., specializes in Experimental Physiology at the National & Kapodistrian University of Athens Medical School, currently serving as a National Center Manager and Assistant Professor. His scholarly contributions encompass extensive investigations into muscle regenerative physiology, IGF-1 functional roles in skeletal tissue homeostasis, post-exercise IGF-1 isoform expression patterns, MGF E peptide characterization, and molecular mechanisms governing exercise-induced gene regulation.

Dr. Anastasios Philippou, Ph.D. is acknowledged for his significant scientific contributions to IGF1-LR3 research and development; however, this acknowledgment does not constitute endorsement, recommendation, or advocacy for commercial acquisition, distribution, or application of this product. No formal association or implicit relationship exists between Peptide Sciences and this investigator. Citation serves solely to recognize and attribute the rigorous investigative efforts undertaken by the scientific community studying this compound. Dr. Anastasios Philippou, Ph.D. appears in references [7] and [8].

Cited References

[1] "Adipose Tissue-Derived Stem Cell Secreted IGF-1 Protects Myoblasts from the Negative Effect of Myostatin," [Online]. Available: https://www.hindawi.com/journals/mi/2014/129048/. [Accessed: 16-May-2019].

[2] N. Li, Q. Yang, R. G. Walker, T. B. Thompson, M. Du, and S. O. Rodgers, "Myostatin Attenuation In Vivo Reduces Adiposity, but Activates Adipogenesis," Endocrinology, vol. 157, no. 1, pp. 282–291, Jan. 2016.

[3] E. Corpas, S. M. Harman, and M. R. Blackman, "Human growth hormone and human aging," Endocr. Rev., vol. 14, no. 1, pp. 20–39, Feb. 1993.

[4] W. E. Sonntag, A. Csiszar, R. deCabo, L. Ferrucci, and Z. Ungvari, "Diverse roles of growth hormone and insulin-like growth factor-1 in mammalian aging: progress and controversies," J. Gerontol. A. Biol. Sci. Med. Sci., vol. 67, no. 6, pp. 587–598, Jun. 2012.

[5] "IGF hGH/IGF system: metabolism outline and physical exercise. - PubMed - NCBI." [Online]. Available: https://www.ncbi.nlm.nih.gov/pubmed/22714057. [Accessed: 16-May-2019].

[6] B. Y. Hanaoka, C. A. Petersen, C. Horbinski, and L. J. Crofford, "Implications of glucocorticoid therapy in idiopathic inflammatory myopathies," Nat. Rev. Rheumatol., vol. 8, no. 8, pp. 448–457, Aug. 2012.

[7] A. Philippou, A. Halapas, M. Maridaki, M. Koutsilieris: Musculoskeletal Neuronal Interact, 2007 [Semantic Scholar].

[8] A. Philippou, E. Papageorgiou, G. Bogdanis, A. Halapas: In vivo, 2009 [Inter Journals].